Health Canada has not approved Retatrutide for any indication, meaning current access outside clinical trials falls into regulatory gray areas
Circulation 145 , 575585 (2022)
The goal is to minimize the rebound, not eliminate it entirely
MOTS-c is the cleaner head-to-head: same exercise-mimetic category, no carcinogenicity flag complicating the safety chapter
However, unlike the natural hormone, which breaks down in minutes, agonists are chemically modified to resist degradation, allowing them to remain active in the body for hours or days to provide continuous metabolic control
Molecular Biology Laboratory studies continue exploring peptide-receptor binding mechanisms and downstream cellular signaling